First-in-Class, Pancreas-Activable Biologic with Dual Mechanism of Action.

TRS-001 is the first therapeutic candidate emerging from our tissue-activable platform—a pancreas-targeted biologic designed to address the underlying immune dysregulation in Type 1 Diabetes (T1D).

T1D is a chronic autoimmune disease in which immune cells, pathogenic T cells, destroy insulin-producing beta cells. Existing therapies fail to address the root cause and often lack durability or safety.

TRS-001 introduces a dual mechanism of action:

• Neutralizing pathogenic effector cells that drive beta cell destruction to stop disease progression
• Boosting regulatory T cells (Tregs) to restore immune balance and support long-term remission

Because TRS-001 activates only within the pancreas, it dramatically reduces systemic exposure and associated risks—enabling higher potency with a superior safety profile.

TRS-001 represents a first-in-class, organ-selective approach with the potential to transform the treatment paradigm for T1D.